Abbott Laboratories (ABT) 10-Q2023 Q2 Quarterly report

Filed: 3 Aug 23, 4:07pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ablation, abnormal, affirmative, Andrea, attributable, chamber, Commerce, complimentary, contact, defense, Department, discontinuation, dual, electrode, eligible, Enabled, Eterna, fibrillation, finalized, flexible, force, HIB, intended, Opportunity, pacing, President, qualify, recognition, recovering, regulatory, sensing, subtraction, TactiFlex, tip, valuation, Vice, Wainer, zone

Removed: Asia, southeast

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABT transcripts

ABT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer
August 3, 2023

A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.